Literature DB >> 24712851

Does body mass index impact the outcomes of tubeless percutaneous nephrolithotomy?

Nicholas J Kuntz1, Andreas Neisius, Gastón M Astroza, Matvey Tsivian, Muhammad W Iqbal, Ramy Youssef, Michael N Ferrandino, Glenn M Preminger, Michael E Lipkin.   

Abstract

OBJECTIVE: To evaluate whether body mass index (BMI) has an impact on the outcomes of tubeless percutaneous nephrolithotomy (PCNL). PATIENTS AND METHODS: We retrospectively reviewed patients who underwent tubeless PCNL at our institution from 2006 to 2011. Specifically, stone-free rates, complications, and hospital length of stay (LOS) were assessed. Patients were divided into four groups based on BMI: <25, 25-29.9, 30-34.9 and ≥35 kg/m(2) . Baseline characteristics and outcomes were compared between BMI groups. Multivariable logistic regressions were used to evaluate the independent contribution of BMI as a predictor of outcomes.
RESULTS: We identified 268 patients who fulfilled study requirements. The overall stone-free and complication rates were 52.5% and 19.0%, respectively. Minor and severe complication comprised 10.4% and 8.6%, respectively. Univariate and multivariable analyses showed no association between BMI and stone-free or complication rates. However, patients with a normal BMI had significantly higher transfusion rates (P = 0.005), and were significantly more likely to have a prolonged LOS (≥2 days), when compared with an overweight BMI (P = 0.032)
CONCLUSIONS: BMI did not impact the stone-free, or complication rates of tubeless PCNL. Normal BMI was found to be a risk factor for prolonged LOS, which may be due to an increase in clinically significant bleeding in this patient population. Tubeless PCNL appears to be a safe and effective procedure for the treatment of complex renal calculi, independent of BMI.
© 2013 The Authors. BJU International © 2013 BJU International.

Entities:  

Keywords:  body mass index; complications; obesity; percutaneous nephrolithotomy; tubeless percutaneous

Mesh:

Substances:

Year:  2014        PMID: 24712851     DOI: 10.1111/bju.12538

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  7 in total

1.  Effectiveness of retrograde intrarenal stone surgery in obese patients.

Authors:  O G Doluoglu; T Karakan; M Kabar; B C Ozgur; A M Hascicek; E Huri; B Resorlu
Journal:  Ir J Med Sci       Date:  2015-11-11       Impact factor: 1.568

2.  Totally tubeless percutaneous nephrolithotomy is feasible in morbidly obese patients.

Authors:  Seyed Mohammad Kazem Aghamir; Mohammad Ghasem Mohseni; Seyed Reza Hosseini; Alborz Salavati; Hossein Ganjali; Mohammad Ali Fallah; Hamed Rezaei; Seyed Saeed Modaresi
Journal:  Turk J Urol       Date:  2017-06-01

3.  Comparison of STONE, CROES and Guy's nephrolithometry scoring systems for predicting stone-free status and complication rates after percutaneous nephrolithotomy in obese patients.

Authors:  Faruk Ozgor; Fatih Yanaral; Metin Savun; Harun Ozdemir; Omer Sarilar; Murat Binbay
Journal:  Urolithiasis       Date:  2017-07-29       Impact factor: 3.436

Review 4.  Effect of Body Mass Index on Outcomes of Percutaneous Nephrolithotomy: A Systematic Review and Meta-Analysis.

Authors:  Yan Xu; Xiaolin Huang
Journal:  Front Surg       Date:  2022-06-14

5.  Ultrasound Guidance to Assist Percutaneous Nephrolithotomy Reduces Radiation Exposure in Obese Patients.

Authors:  Manint Usawachintachit; Selma Masic; Helena C Chang; Isabel E Allen; Thomas Chi
Journal:  Urology       Date:  2016-04-22       Impact factor: 2.649

6.  Skin to calyx distance is not a predictive factor for miniaturized percutaneous nephrolithotomy outcomes.

Authors:  Faruk Ozgor; Onur Kucuktopcu; Burak Ucpinar; Fatih Yanaral; Murat Binbay
Journal:  Int Braz J Urol       Date:  2017 Jul-Aug       Impact factor: 1.541

7.  Outcome of tubeless percutaneous nephrolithotomy in elder patients: A single-center experience from a developing country.

Authors:  Nadeem Iqbal; Sajid Iqbal; Aisha Hasan; Aimen Iqbal; Keron A A Blair; Dan M J Milstein; Saeed Akhter
Journal:  J Clin Transl Res       Date:  2022-03-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.